Report Sections

See All Reports

Coronavirus Infections (808) Severe Acute Respiratory Syndrome (560) Infection (466) Pneumonia (365) Communicable Diseases (197) Respiratory Distress Syndrome, Adult (178) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) (130) Syndrome (105) Virus Diseases (87) Pneumonia, Viral (82) Depression (65) Critical Illness (62) Anxiety Disorders (38) Respiratory Tract Infections (36) Cardiovascular Diseases (35) Emergencies (35) Stress, Psychological (31) Lung Injury (30) Neoplasms (30) Inflammation (29) Stress Disorders, Post-Traumatic (29) Wounds and Injuries (29) Hypoxia (28) Thrombosis (28) Diabetes Mellitus (26) Disease (25) Respiratory Tract Diseases (25) Stress Disorders, Traumatic (25) Depressive Disorder (24) Acute Kidney Injury (22) Disease Progression (22) Lung Diseases (22) Mental Disorders (21) Burnout, Psychological (19) Olfaction Disorders (19) Respiration Disorders (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Fibrosis (12) Arthritis, Rheumatoid (11) Influenza, Human (11) Rheumatic Diseases (11) Venous Thrombosis (11) Dyspnea (10) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Heart Failure (8) Infarction (8) Liver Diseases (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lung Diseases, Obstructive (7) Lymphopenia (7) Multiple Sclerosis (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Pulmonary Disease, Chronic Obstructive (6) Autoimmune Diseases (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Nervous System Diseases (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Adenoviridae Infections (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Colorectal Neoplasms (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypertension, Pulmonary (3) Ischemia (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Initiation and Maintenance Disorders (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Ageusia (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Bacteremia (2) Behcet Syndrome (2) Bipolar Disorder (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) (2) Dementia (2) Depressive Disorder, Major (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Eye Diseases (2) Fever (2) Fibromyalgia (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypersensitivity (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Atrophy (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cerebral Palsy (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) (1) Common Cold (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronavirus Infect (1) (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) Developmental Disabilities (1) DiGeorge Syndrome (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal Neoplasms (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophies (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Myofascial Pain Syndromes (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Reperfusion Injury (1) Resp (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D000857: Olfaction Disorders

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (33)


Name (Synonyms) Correlation
drug2384 Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances Wiki 0.32
drug1848 Low-Concentration Essential Oil Wiki 0.23
drug526 Budesonide Wiki 0.23
Name (Synonyms) Correlation
drug2017 Mindfulness training (MT) Connect Wiki 0.23
drug2107 Nasal lavage Wiki 0.23
drug1764 Late dexamethazone Wiki 0.23
drug2437 Physiological serum Wiki 0.23
drug3878 modified IPAC-UHN PPE Wiki 0.23
drug527 Budesonide Nasal Wiki 0.23
drug3747 corticosteroid nasal irrigation Wiki 0.23
drug3750 current IPAC-UHN PPE Wiki 0.23
drug2266 Omega-3 Fatty Acid Supplement Wiki 0.23
drug2528 Placebo/Control Wiki 0.23
drug1344 General Public cohort Wiki 0.23
drug2287 Ophtamesone Wiki 0.23
drug3880 mometasone furoate nasal spray Wiki 0.23
drug1261 Fast dissolving film Wiki 0.23
drug1635 Insulin film Wiki 0.23
drug1428 High-Concentration Essential Oil Wiki 0.23
drug3919 olfactory and gustatory tests Wiki 0.23
drug2080 NHANES smell and taste tests Wiki 0.23
drug2258 Olfactometry Wiki 0.23
drug3681 assessment of the sequelae after hospitalization for Sars-COV-2 Wiki 0.23
drug2259 Olfactory retraining Wiki 0.23
drug2104 Nasal Irrigation Wiki 0.23
drug1102 ENT exam Wiki 0.23
drug4016 smell household Items Wiki 0.23
drug358 BCG Vaccine Wiki 0.23
drug496 Brain MRI Wiki 0.23
drug497 Brain MRI scan Wiki 0.23
drug1115 Early-Dexamethasone Wiki 0.16
drug2564 Povidone-Iodine Wiki 0.11
drug2448 Placebo Wiki 0.03

Correlated MeSH Terms (8)


Name (Synonyms) Correlation
D004408 Dysgeusia NIH 0.40
D000370 Ageusia NIH 0.32
D013651 Taste Disorders NIH 0.13
Name (Synonyms) Correlation
D004194 Disease NIH 0.09
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03
D014777 Virus Diseases NIH 0.02
D007239 Infection NIH 0.02

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000458 Anosmia HPO 1.00
HP:0000224 Hypogeusia HPO 0.32

Clinical Trials

Navigate: Correlations   HPO

There are 19 clinical trials


1 Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection

Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.

NCT04354857
Conditions
  1. COVID-19
Interventions
  1. Other: olfactory and gustatory tests
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: Positive/negative according to RT-PCR assay

Measure: SARS-CoV-2 infection status

Time: Day 0

Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)

Measure: Olfactory and gustatory loss

Time: Day 0

Secondary Outcomes

Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale

Measure: Ability to detect odor

Time: Day 0

Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale

Measure: Ability to detect odor

Time: Six months

Description: Ability to taste a pinch of table salt on a 0-100 VAS scale

Measure: Ability to detect salty taste

Time: Day 0

Description: Ability to taste a pinch of table salt on a 0-100 VAS scale

Measure: Ability to detect salty taste

Time: Six months

Description: Ability to taste a pinch of sugar on a 0-100 VAS scale

Measure: Ability to detect sweet taste

Time: Day 0

Description: Ability to taste a pinch of sugar on a 0-100 VAS scale

Measure: Ability to detect sweet taste

Time: Six months

Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)

Measure: Olfactory and gustatory loss

Time: Day 7

Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)

Measure: Olfactory and gustatory loss

Time: Day 14

Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)

Measure: Olfactory and gustatory loss

Time: Day 30

Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)

Measure: Olfactory and gustatory loss

Time: Day 60

Description: % patients hospitalized

Measure: Severity of infection according to hospitalization rate

Time: End of study (six months)

Description: Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste)

Measure: Olfactory and gustatory loss

Time: Six months
2 A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity

The initial symptoms described in the first cases of COVID-19 were mainly fever and respiratory signs. Recently, there has been an increase in cases of hyposmia without associated nasal obstruction or rhinorrhea. Although we do not yet know the long-term consequences of COVID-19 on olfaction, there is evidence in the literature demonstrating that post-viral hyposmias are an important source of long-term olfactory disorders, impacting quality of life. Usually, the treatment of viral hyposmias is based on local and/or general corticosteroid treatment combined with saline nasal irrigation at the onset of signs. Because of the possible development of severe forms of the SARS-Cov-2 infection, the French Society of Otorhinolaryngology has advised against treatment by corticosteroid therapy and nasal irrigation. However, as the virus is present in the nasal fossae on average for 20 days, persistent hyposmia at 30 days would probably result from an inflammatory or neurological damage to the nasal slits or olfactory bulb. Local treatment with corticosteroids could then be instituted from 30 days after the onset of symptoms of COVID-19 without risk of dissemination. In persistent hyposmia other than chronic rhinosinusitis, the only treatment that has proven its efficacy is nasal irrigation associated with budesonide and olfactory rehabilitation. However, this drug does not have marketing authorisation in France for this indication.

NCT04361474
Conditions
  1. Budesonide
  2. Olfaction Disorders
  3. SARS-CoV-2
  4. Anosmia
Interventions
  1. Drug: Budesonide Nasal
  2. Other: Physiological serum
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: Percentage of patients with an improvement of more than 2 points on the ODORATEST score (5) after 30 days of treatment

Measure: Patient with more than 2 points on the ODORATEST

Time: 30 days
3 Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial

The study will be a randomized controlled trial, involving patients with hyposmia/anosmia of onset immediately after an upper respiratory viral illness, assigned to three distinct study arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care) and act as a control group. The second group will receive an essential oil retraining kit, whereas the third group will receive the same olfactory training kit and a prescription to use budesonide with the nasal irrigations. Olfactory scores will be tested at the enrollment, 3 months and at 6 months.

NCT04374474
Conditions
  1. Olfactory Disorder
Interventions
  1. Other: Olfactory retraining
  2. Drug: corticosteroid nasal irrigation
  3. Other: smell household Items
  4. Other: Nasal Irrigation
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: Score from the Snap and Sniff Olfactory Test results

Measure: Change from Baseline Snap and Sniff Threshold Test at 3 months

Time: 3 months

Description: Score from the Smell Identification test results.

Measure: Change from baseline Smell Identification Test (SIT) at 3 months

Time: 3 months

Description: Score from the Snap and Sniff Olfactory Test results

Measure: Change from Baseline Snap and Sniff Threshold Test at 6 months

Time: 6 months

Description: Score from the Smell Identification test results.

Measure: Change from baseline Smell Identification Test (SIT) at 6 months

Time: 6 months

Secondary Outcomes

Description: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)

Measure: Change from baseline QOD-NS at 3 months

Time: 3 months

Description: Short Form 36 Health Survey scores

Measure: Change from baseline SF-36 health survey at 3 months

Time: 3 months

Description: Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)

Measure: Change from baseline QOD-NS at 6 months

Time: 6 months

Description: Short Form 36 Health Survey scores

Measure: Change from baseline SF-36 health survey at 6 months

Time: 6 months

Description: Adherence comparison between participants post-CoVID 19 and patients post other viral infections.

Measure: Adherence to the Study Protocol

Time: 6 months

Description: Compare the rate of recovery between post-COVID 19 patients and patients post other viral infections.

Measure: Recovery

Time: 6 months
4 FORECAST Study: Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste

The FORECAST Study is an observational cohort study looking at two cohorts of patients presenting with COVID-19: a general public cohort, aiming to investigate if new loss or reduced sense of smell and/or taste are early signs of COVID-19 and a hospital cohort, which will investigate if taste/smell changes can predict the clinical course of a COVID-19 infection.

NCT04377815
Conditions
  1. COVID-19
  2. Anosmia
Interventions
  1. Other: General Public cohort
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: percentage of people who report loss/reduced sense of smell or taste

Measure: Percentage of people reporting changes in smell/taste

Time: 4 weeks

Description: to compare the case mortality rate in COVID-19 patients who experienced smell/taste changes compared to mortality in those who did not experience smell/taste changes.

Measure: mortality rate

Time: through study completion, an average of 1 year

Secondary Outcomes

Description: To identify the percentage of people who report changes in taste and/or smell before developing either fever or persistent cough who are positive for SARS-CoV-2 IgM and IgG

Measure: Percentage of people with change in smell/taste before other symptoms

Time: 4 weeks

Description: To examine the proportion of other COVID-19 linked symptoms in people with smell and/or taste change who are positive positive for SARS-CoV-2 IgM and IgG who never develop fever and/or cough.

Measure: proportion of other COVID-19 linked symptoms in people with smell and/or taste change

Time: 4 weeks

Description: To determine the percentage of people whose smell and/or taste symptoms persist for greater than 4 weeks in people who are positive for SARS-CoV-2 IgM and IgG

Measure: Percentage of people with persistent changes in smell and/or taste

Time: 12 weeks

Description: To determine the percentage of patients who report loss/decrease in sense of smell and/or taste changes before or in the absence of other symptoms of COVID-19, who are admitted to hospital with COVID-19

Measure: Percentage of hospitalisation

Time: 12 weeks

Description: To investigate whether loss/reduced sense of smell and/or taste are associated with the course of illness and outcomes in COVID-19

Measure: co-morbidities association

Time: through study completion, an average of 1 year

Description: Assessing the prevalence of previous loss/decrease in sense of smell and/or taste changes in patients admitted to secondary care with COVID-19 infection.

Measure: prevalence of changes in smell/taste

Time: through study completion, an average of 1 year

Description: Correlating the presence of loss/decrease in sense of smell and/or taste changes to clinical outcomes including case fatality rate.

Measure: clinical outcomes

Time: through study completion, an average of 1 year
5 Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Case-Control Study

The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection. This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The case-control study is described here (the cross-sectional study is described in a separate ClinicalTrials.gov record).

NCT04384042
Conditions
  1. SARS-CoV Infection
  2. COVID-19
  3. Anosmia
  4. Dysgeusia
Interventions
  1. Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Olfaction Disorders Dysgeusia
HPO:Anosmia

Primary Outcomes

Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances

Measure: Presence or absence of olfactory and taste disturbances in study participants

Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infection

Description: The relationship between case & control status and each exposure variable will be estimated by odds ratios and their 95% confidence intervals using conditional logistic regression models.

Measure: Adjusted odds ratio of olfactory & taste disturbances in COVID-19 infection

Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infection

Secondary Outcomes

Description: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19/within the past 2 weeks of answering the questionnaire (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)

Measure: Clinical manifestations of study participants

Time: 2 weeks prior to answering questionnaire/ prior to diagnosis of COVID-19 infection

Description: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)

Measure: Other pre-existing health conditions

Time: Baseline

Description: PPV reflects the probability that the presence of olfactory and taste disturbances will have a positive diagnosis of COVID-19. This is derived from dividing the number of patients with olfactory & taste disturbances with COVID-19 infection over the total number of patients with olfactory and taste disturbances, and multiplying by 100%

Measure: Positive predictive value (PPV) of olfactory and taste disturbances in predicting diagnosis of COVID-19 infection

Time: Baseline

Description: NPV reflects the probability that the absence of olfactory and taste disturbances will have a negative diagnosis of COVID-19. This is derived from dividing the number of patients without olfactory & taste disturbances and without COVID-19 infection over the total number of patients with no olfactory and taste disturbances, and multiplying by 100%

Measure: Negative predictive value (NPV) of olfactory and taste disturbances in predicting absence of COVID-19 infection

Time: Baseline

Description: The percentage of true positives, i.e. the proportion of patients with olfactory and taste disorders with COVID-19 infection. This can be calculated by dividing the number of subjects with olfactory & taste disturbances who have COVID-19 infection with the number of patients with olfactory & taste disturbances, and multiplying by 100%

Measure: Sensitivity of olfactory and taste disturbances in predicting COVID-19 infection

Time: Baseline

Description: The percentage of true negatives, i.e. the proportion of patients without olfactory and taste disorders who do not have COVID-19 infection. This can be calculated by dividing the number of subjects without olfactory & taste disturbances who do not have COVID-19 infection with the number of patients without olfactory & taste disturbances, and multiplying by 100%

Measure: Specificity of olfactory and taste disturbances in predicting COVID-19 infection

Time: Baseline
6 Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia

COVID-19 has adversely affected the healthcare system across the world. The world was not prepared for global outbreak of infectious diseases. The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is enabling researchers worldwide to acquire a large amount of clinical data regarding coronavirus disease (COVID-19). The COVID-19 infection severely affects the respiratory system in the critical cases and results in mortalities. The affected people experience a dry cough, fever, breathing problems, diarrhea, muscle pain, and sore throat. Besides that, some of the evidence from Italy, South Korea, China, and Spain suggest that the COVID-19 cases also lose their senses of smell and taste resulting in alterations in those patients. The objective of this proposed study is to determine whether COVID-19 cases have Olfactory and gustatory dysfunctions as a hallmark indicator and can be used as diagnostic tools for the isolation of suspected people. Investigators are presenting a prospective proportional case-control study that is conducted to investigate the COVID-19 cases with anosmia and /or Ageusia in a university hospital in Riyadh, Saudi Arabia. The sample size of this case series would be 250 cases of suspected COVID-19 patients. The cases included in the study are analyzed prospectively to determine if the cases had a history of anosmia and /or Ageusia, and then tested for the alteration of these senses through a panel of standardized odors/taste strips. That is looked at statistically allowing us to confirm the proposed effectiveness of these tests as a diagnostic tool.

NCT04388618
Conditions
  1. Anosmia
  2. Ageusia
  3. Covid19
  4. Corona Virus Infection
Interventions
  1. Other: NHANES smell and taste tests
MeSH:Virus Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Olfaction Disorders Ageusia
HPO:Anosmia Hypogeusia

Primary Outcomes

Description: to how extent alteration of smell and taste senses is related to covid19 status

Measure: correlation of anosmia and ageusia to covid19 positive patients

Time: from 1/06/2020 to 31/12/2020

Secondary Outcomes

Description: to determine the range of sense affection ranging from total loss to mild form

Measure: objective assessment of severity of smell and taste senses alterations in covid19 patients

Time: from 1/06/2020 to 31/12/2020
7 Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Cross-Sectional Study

The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to evaluate the predictive value of screening for these symptoms in COVID-19 infection. This study consists of two phases: the first phase is a cross-sectional study and the second phase is a case-control study. The cross-sectional study is described here (the case-control study is described in a separate ClinicalTrials.gov record).

NCT04390165
Conditions
  1. SARS-CoV Infection
  2. COVID-19
  3. Anosmia
  4. Dysgeusia
Interventions
  1. Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome Olfaction Disorders Dysgeusia
HPO:Anosmia

Primary Outcomes

Description: In the patient-reported online questionnaire, subjects will be asked regarding whether they experienced symptoms of olfactory and/or taste disturbances

Measure: Presence or absence of olfactory and taste disturbances in COVID-19 patients

Time: Within 2 weeks preceding the diagnosis of COVID-19 infection

Description: Percentage of COVID-19 patients experiencing olfactory disturbances (anosmia or hyposmia)

Measure: Prevalence of olfactory disturbances in COVID-19 patients

Time: Within 2 weeks preceding the diagnosis of COVID-19 infection

Description: Percentage of COVID-19 patients experiencing taste disturbances

Measure: Prevalence of taste disturbances in COVID-19 patients

Time: Within 2 weeks preceding the diagnosis of COVID-19 infection

Secondary Outcomes

Description: In the patient-reported online questionnaire, subjects will be asked regarding other symptoms they experienced when they were diagnosed with COVID-19 (e.g. headache, nasal congestion, fever, chills, cough, dyspnoea, gastrointestinal symptoms, eye & ear symptoms)

Measure: Clinical manifestations of study participants

Time: Within 2 weeks preceding the diagnosis of COVID-19 infection

Description: In the patient-reported online questionnaire, subjects will be asked regarding their pre-existing health conditions (for example, obesity, diabetes, hypertension, cardiac conditions, previous head trauma, chronic rhinosinusitis, etc.)

Measure: Other pre-existing health conditions

Time: Prior to diagnosis of COVID-19 infection

Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste before their diagnosis of COVID-19 infection

Measure: Rating of baseline sense of smell & taste in COVID-19 patients prior to diagnosis of their infection

Time: Prior to 2 weeks preceding the diagnosis of COVID-19 infection (Baseline)

Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of diagnosis of COVID-19 infection

Measure: Rating of sense of smell & taste in COVID-19 patients at time of diagnosis of their infection

Time: Within 2 weeks preceding the diagnosis of COVID-19 infection

Description: In the patient-reported online questionnaire, subjects will be asked to rate their sense of smell and taste at the time of answering questionnaire survey

Measure: Rating of sense of smell & taste in COVID-19 patients at time of answering questionnaire survey

Time: Up to 6 months
8 Descriptive Pilot Study of Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia

To date there is no brain imaging and olfactory data available in COVID-19 positive patients with anosmia. By describing the pathophysiological characteristics underlying the olfactory symptoms and clinical characteristics of COVID-19 infection, the study investigators wish to compare the MRI aspects obtained in COVID-19 patients with and without anosmia, in the absence of other underlying neurological disorders.

NCT04408391
Conditions
  1. Covid-19
  2. Anosmia
Interventions
  1. Other: Brain MRI scan
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: MRI; Voxels

Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia

Time: Day 0

Secondary Outcomes

Description: MRI; Voxels

Measure: Brain regional homogeneity between COVID-19 patients with and without anosmia

Time: Month 3

Description: MRI; Voxels

Measure: Topography of supra- or sub-tentorial lesions between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; voxels, value between 0-1

Measure: Fractional anisotropy between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; voxels, value between 0-1

Measure: Fractional anisotropy between COVID-19 patients with and without anosmia

Time: Month 3

Description: MRI; mm2/s

Measure: Mean diffusivity between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; mm2/s

Measure: Mean diffusivity between COVID-19 patients with and without anosmia

Time: Month 3

Description: MRI; mm2/s

Measure: Radial diffusivity between COVID-19 patients with and without anosmia

Time: Day 0

Description: MRI; mm2/s

Measure: Radial diffusivity between COVID-19 patients with and without anosmia

Time: Month 3

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Day 0

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Day 8

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Month 1

Description: Four questions measured by 0-100 visual analogue scale: how do you rate the quality of your sense of smell/taste normally/today

Measure: Self-assessed olfactory and gustatory test

Time: Month 2

Description: Ability to smell 1.5ml air freshner on a 0-100 VAS scale (cut-offs: strang (>80), moderate (40-80), attenuated (<40)

Measure: Ability to detect odor

Time: Day 0

Description: Patient asked to describe whether a pinch of sugar on their tongue taste sweet or salty

Measure: Ability to taste a pinch of sugar

Time: Day 0

Description: MRI: absence/presence

Measure: Presence of thrombotic and hemorrhagic lesions

Time: Day 0

Description: MRI: absence/presence

Measure: Presence of thrombotic and hemorrhagic lesions

Time: Month 3

Description: Short Ti Inversion Recovery (STIR); presence/absence

Measure: Presence of lesions with hyperintensity

Time: Day 0

Description: Short Ti Inversion Recovery (STIR); presence/absence

Measure: Presence of lesions with hyperintensity

Time: Month 3

Description: beta voxels

Measure: Projection network analysis of all patients

Time: Day 0

Description: beta voxels

Measure: Projection network analysis of all patients

Time: Month 3

Description: beta voxels

Measure: Blinded independent component analysis of all patients

Time: Day 0

Description: beta voxels

Measure: Blinded independent component analysis of all patients

Time: Month 3

Description: beta voxels

Measure: default mode network analysis of all patients

Time: Day 0

Description: beta voxels

Measure: default mode network analysis of all patients

Time: Month 3

Description: beta voxels

Measure: executive control network analysis of all patients

Time: Day 0

Description: beta voxels

Measure: executive control network analysis of all patients

Time: Month 3
9 Coronavirus Smell Therapy for Anosmia Recovery

As the COVID-19 pandemic spread around the world, anosmia and dysgeusia were quickly recognized as two of the key presenting symptoms. The probability of return of smell is related to severity of smell loss at presentation, but it appears that the loss of sense of smell and taste seems to persist in approximately 10% of the affected patients after 6 months. As a result of COVID-19, it is estimated that within the next 12 months > 150,000 Americans will suffer permanent loss of smell. The magnitude of this impairment on the health, safety, and quality of life is truly unprecedented and makes post-COVID olfactory disorder a major public health problem. Thus, there is a pressing need to identify effective treatments. The research questions are to determine the effects of steroid nasal saline lavage and olfactory training among adults with post-COVID olfactory dysfunction and identify confounders and modifiers of any observed effects. To answer the research question, the investigators propose a 2 x 2 factorial design blinded randomized clinical trial whereby 220 subjects with documented COVID-19 with anosmia/hyposmia of 12 weeks duration or longer from Missouri, Illinois, and Indiana will be recruited electronically from COVID patient advocacy sites, social media sites, and other internet sources. Enrolled subjects will be randomized to nasal saline lavage with topical budesonide or placebo to address the presumed role of inflammation in the olfactory cleft and each subject will also be randomized to olfactory training with patient-specific, high- or low-concentration essential oil scent to assess the role of olfactory training. Data will be analyzed in a blinded fashion to allow estimation of observed effect size for both anti-inflammatory and olfactory training. This innovative study will exploit the unique opportunities presented by COVID-19. The study will use a high-tech virtual "contactless" research strategy, including eConsent and digital mHealth techniques to obtain rapid answers to the research questions. The interventions are low-cost, readily available, and results of this study can be directly disseminated to the care of COVID-19 patients with anosmia.

NCT04422275
Conditions
  1. Anosmia
Interventions
  1. Drug: Budesonide
  2. Behavioral: High-Concentration Essential Oil
  3. Drug: Placebo
  4. Behavioral: Low-Concentration Essential Oil
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: The University of Pennsylvania Smell Identification Test (UPSIT) (Sensonics, New Jersey)7 is the most widely accepted olfactory identification test in North America. The UPSIT consists of four 10-page booklets, with a total of 40 items. Subjects are asked to scratch each strip with a pencil to release the scents, detect the smell, and identify the smell from the four choice options. The UPSIT comes from a scoring rubric that identifies the normalcy benchmark based on age and gender. Normosmia is defined as ≥34 for males and ≥35 for females, and an increase of 4 points or more from baseline indicates a clinically meaningful improvement. UPSIT has high internal reliability across a wide range of populations.

Measure: University of Pennsylvania Smell Identification Test (UPSIT)

Time: The within subject change in UPSIT between baseline and 12- and 24-week assessment time frame.

Secondary Outcomes

Description: The Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS) was adapted from the original 52-item Questionnaire of Olfactory Disorders. This short-modified version is a validated 17-item questionnaire about quality of life and impairments related to olfactory dysfunction. The maximum score is 51, and higher values indicate worse quality of life or higher degree of impairment of normal daily activity. Mean scores in anosmics is 19; hyposmics is 8; and normosmics is 0. Prior studies used a cutoff score of 12.5 to reflect normal vs. abnormal scores.The minimum clinically important difference is 5.2.

Measure: Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).

Time: The within subject change in QOD-NS between baseline and assessment time frame.

Description: The Global Rating of Smell is a single-item, global rating that asks: "Overall, please rate your current sense of smell? Excellent, Very Good, Good, Fair, Poor, Absent."

Measure: Global Rating of Smell.

Time: 12 weeks - End of nasal lavage & olfactory training; 24 weeks - Follow-up (12 weeks after completion of lavage & training)

Description: The Global Rating of Smell Change is a single-item, global rating that asks: "Compared to your sense of smell # weeks ago, how would you rate your change in smell since then? Much better, Somewhat better, Slightly better, Neither better nor worse, Slightly worse, Somewhat worse, or Much worse." The time frame ("#") will be changed to reflect the correct time since enrollment (i.e., 12, or 24 weeks).

Measure: Global Rating of Smell Change.

Time: 12 weeks - End of olfactory training; 24 weeks - Follow-up (12 weeks after completion of lavage & training)
10 Objective Assessment of Olfactory Dysfunction and Impact on Quality of Life in SARS CoV-2 (COVID-19)Infection Using the UPSIT, eQOD and SNOT-22 Questionnaires: A Prospective Observational Cohort Study

This study is designed to investigate the acuity of olfactory dysfunction in COVID-19 positive patients in the United Kingdom. In particular defining severity with objective testing and determining if this has any predictive value on the outcome of the SARS CoV-2 infection. In addition, this study will strive to determine duration / natural history of olfactory dysfunction in these patients in respect to a positive SARS CoV-2 diagnosis. It should also demonstrate the impact of olfactory dysfunction on patient Quality of Life (QOL).

NCT04466982
Conditions
  1. Olfactory Disorder
  2. COVID19
  3. SARS-CoV-2
  4. Anosmia
  5. Microsomia
  6. Smell Disorder
  7. Quality of Life
MeSH:Olfaction Disorders Disease
HPO:Anosmia

Primary Outcomes

Description: I. Primary endpoint is olfactory function assessed using the UPSIT and classified as Anosmia; Mild, moderate, and severe microsomia. assessed at the time COVID-19 diagnosis (+1 week) or at the time of registration for in hospital patients

Measure: UPSIT scores

Time: At time of diagnosis (+1 week ) post COVID 19 diagnosis or at time of recruitment into study

Secondary Outcomes

Description: I. The changes in olfaction in patients with SARS CoV-2 infection over an initial 12 month period (at day 0, 1 month, 3 month, 6 month, 9 month and 12 month) using the UPSIT.

Measure: UPSIT scores

Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 month

Description: Quality of Life using the validated Questionnaire of Olfactory Disorders for English speakers (eQOD)

Measure: eQOD scores

Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 month

Description: Quality of Life using the validated SinoNasal Outcome Tool-22 (SNOT-22)

Measure: SNOT 22 scores

Time: at day 0, 1 month, 3 month, 6 month, 9 month and 12 month
11 Detection of SARS-CoV-2 in Patients Presenting With Anosmia During COVID-19 Pandemic Era in Egypt

The study aims to test the frequency of severe acute respiratory syndrome new corona virus SARS-CoV-2 or other respiratory viruses in patients presenting with anosmia or dysgeusia to Ain Shams University Hospitals, Cairo, Egypt.

NCT04473157
Conditions
  1. Anosmia
  2. Covid19
  3. Dysgeusia
MeSH:Olfaction Disorders Dysgeusia
HPO:Anosmia

Primary Outcomes

Description: subjective questionnaire about smell and taste

Measure: Recovery from Anosmia

Time: 3 weeks

Description: developing IgM/ IgG antibodies by rapid test

Measure: Seroconversion

Time: 3 weeks

Secondary Outcomes

Description: developing other symptoms of COVID 19

Measure: COVID 19

Time: 3 weeks
12 Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients

The aim of this study is to evaluate the role of the topical corticosteroids nasal spray (mometasone furoate nasal spray) in improving anosmia in patients recovered from COVID-19 infection.

NCT04484493
Conditions
  1. Covid19
  2. Anosmia
Interventions
  1. Drug: mometasone furoate nasal spray
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: The patient will report the degree of anosmia subjectively with score on a scale from 0 to 10 (0 means total loss of smell and 10 refers to completely normal smell sensation).

Measure: improvement of olfaction

Time: 3 weeks
13 COVID-19 Anosmia Study

To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.

NCT04495816
Conditions
  1. Anosmia
  2. Covid19
Interventions
  1. Drug: Omega-3 Fatty Acid Supplement
  2. Drug: Placebo/Control
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: Brief Smell Identification Test (BSIT) is a 12-item instrument, full range score from 0 to 12, higher score indicates better olfactory performances.

Measure: Brief Smell Identification Test (BSIT)

Time: Week 0

Description: Brief Smell Identification Test (BSIT) is a 12-item instrument, full range score from 0 to 12, higher score indicates better olfactory performances.

Measure: Brief Smell Identification Test (BSIT)

Time: 6 weeks after beginning to take supplements

Secondary Outcomes

Description: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 1 week after softgel initiation

Description: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 2 weeks after softgel initiation

Description: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 4 weeks after softgel initiation

Description: The modified Brief Questionnaire of Olfactory Dysfunction - Negative Statements (QOD-NS) survey is a 17-item instrument, each item graded on a scale from 0 to 3, with total scale range from 0 to 51. Higher score indicates better olfactory-specific quality of life (QOL).

Measure: Modified Brief Questionnaire of Olfactory Dysfunction (mQOD-NS)

Time: 6 weeks after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 1 week after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 2 weeks after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 4 weeks after softgel initiation

Description: Sino-Nasal Outcome Test (SNOT-22) is a 22-item instrument, total scale range from 0 to 110, higher score indicates more severe QOL impact.

Measure: Sinonasal Outcomes Test (SNOT-22)

Time: 6 weeks after softgel initiation
14 Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19

Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients with COVID-19

NCT04524754
Conditions
  1. Anosmia
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: subjective on a scale from 1 to 5 ( 1 is the least and 5 is the best ) , the score will be recorded for olfaction before and after the olfactory loss

Measure: olfaction

Time: one month

Secondary Outcomes

Description: subjective on a scale from 1 to 5 ( 1 is the least and 5 is the best ) , , the score will be recorded for gustation before and after the gustatory loss

Measure: gustation

Time: one month
15 Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients

Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients. This study aimed to detect these disturbances among positive COVID-19 patients (symptom not initially highlighted by the patient and not sought by caregivers) in order to allow early management of olfactory and gustatory dysfunction.

NCT04526054
Conditions
  1. Olfaction Disorders
  2. COVID-19
Interventions
  1. Diagnostic Test: ENT exam
  2. Diagnostic Test: Olfactometry
  3. Diagnostic Test: Brain MRI
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner.

Measure: To compare the qualitative and quantitative morphological abnormalities of the olfactory bulb detected by MRI on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.

Time: initial examination

Description: Sniffin' test score (T threshold score, D discrimination score, I identification score).

Measure: To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.

Time: initial examination

Secondary Outcomes

Description: Intensity ratio calculated between average signals of the olfactory bulb and the frontal white matter on a 3-Tesla MRI scanner at initial examination, between 6 weeks and 2 months and between 6 and 9 months.

Measure: Longitudinal evaluation of qualitative and quantitative abnormalities of olfactory bulbs on MRI in in COVID-19 anosmic patient at initial examination, between 6 weeks and 2 months and between 6 and 9 months.

Time: initial examination, 6 week to 2 months, 6 to 9 months

Description: Sniffin' test score (T threshold score, D discrimination score, I identification score).

Measure: To compare the result of the olfactometry (Sniffin' test) on initial examination in COVID-19 anosmic versus COVID-19 normosmic patients.

Time: initial examination, 6 week to 2 months, 6 to 9 months
16 Time to Recover of Anosmia and / or Ageusia and Early Corticosteroid Use

Time to recover of Anosmia and / or ageusia and early corticosteroid use

NCT04528329
Conditions
  1. Covid19
  2. Anosmia
Interventions
  1. Drug: Early-Dexamethasone
  2. Drug: Late dexamethazone
MeSH:Olfaction Disorders Ageusia
HPO:Anosmia Hypogeusia

Primary Outcomes

Description: Time to recovery from anosmia and / or agusia

Measure: Time to recovery

Time: one to 6 weeks
17 Taste and Smell Impairment in Critically Ill COVID-19 Patients

Evaluating the smell and taste perceptions of patients hospitalized in the intensive care unit with suspicion of Coronavirus disease-19 diagnosis with a survey study

NCT04532632
Conditions
  1. Smell Disorder
  2. Taste Disorders
  3. Coronavirus Infection
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Taste Disorders Olfaction Disorders Disease
HPO:Anosmia

Primary Outcomes

Description: incidence of taste and smell impairment in critically ill subjects

Measure: taste and smell impairment

Time: up to 3 months
18 Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease

Background: Anosmia is a debilitating common symptom of COVID-19. The therapeutic effect of systemic steroid for the treatment of anosmia has been studied with various findings of its efficacy. However, the effect of local steroid was not assessed before. Objective: To estimate the efficacy of local steroid in the treatment of anosmia in COVID-19 patients.

NCT04569825
Conditions
  1. Clinical Trial
Interventions
  1. Drug: Ophtamesone
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: To estimate the recovery rate for both groups and whether nasal steroid enhance the recovery time

Measure: Recovery rate of anosmia and shorten recovery time

Time: 30 days
19 "Insulin Fast Dissolving Film for Intranasal Delivery Via Olfactory Region, a Promising Approach for the Treatment of Anosmia in COVID 19 Patients: Design, In-vitro Characterization and Clinical Evaluation."

The study aimed to investigate the efficacy of insulin in a new dosage form ( fast dissolving film) in treatment of anosmia in patients post infested with Covid-19. The study implication based in two methods evaluations 1. Threshold test 2. identification test.

NCT04657809
Conditions
  1. Anosmia
Interventions
  1. Combination Product: Insulin film
  2. Device: Fast dissolving film
MeSH:Olfaction Disorders
HPO:Anosmia

Primary Outcomes

Description: By decrease the threshold sensation with butanol test

Measure: Smell sensation improvement

Time: 4 weeks

HPO Nodes


Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook